ID   U-343MG
AC   CVCL_S471
SY   U-343 MG; U-343-MG; U343MG; U-343; U343; 343 MG; 343MG; 343 MG(9)
DR   BTO; BTO:0006221
DR   EFO; EFO_0022447
DR   Cell_Model_Passport; SIDM01495
DR   Cosmic; 849880
DR   Cosmic; 2367503
DR   Cosmic; 2491104
DR   Cosmic; 2516043
DR   Cosmic; 2701086
DR   Wikidata; Q54973568
RX   DOI=10.1007/0-306-46861-1_11;
RX   DOI=10.1007/978-1-4757-1647-4_7;
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RX   PubMed=77569;
RX   PubMed=1847665;
RX   PubMed=2454731;
RX   PubMed=3518877;
RX   PubMed=3675803;
RX   PubMed=4134536;
RX   PubMed=4142792;
RX   PubMed=4359449;
RX   PubMed=4369403;
RX   PubMed=6260907;
RX   PubMed=10402232;
RX   PubMed=10416987;
RX   PubMed=11351043;
RX   PubMed=21061448;
RX   PubMed=21406405;
RX   PubMed=22570425;
RX   PubMed=25984343;
RX   PubMed=26496030;
RX   PubMed=27582061;
RX   PubMed=33385022;
CC   Population: Caucasian.
CC   Doubling time: 45 hours (PubMed=25984343).
CC   HLA typing: A*02,03; B*07,27 (PubMed=77569).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Brain, temporal lobe; UBERON=UBERON_0001871.
ST   Source(s): PubMed=22570425; PubMed=27582061
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 9,13
ST   D16S539: 9,12
ST   D18S51: 21,23 (PubMed=27582061)
ST   D18S51: 23 (PubMed=22570425)
ST   D19S433: 13,14
ST   D21S11: 31,33.2
ST   D2S1338: 22,24
ST   D3S1358: 15,17
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   D8S1179: 13,14
ST   FGA: 19,20
ST   Penta D: 9,10
ST   Penta E: 10,12
ST   TH01: 6,9.3
ST   TPOX: 8,9
ST   vWA: 17 (PubMed=22570425)
ST   vWA: 17,18 (PubMed=27582061)
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_4773 ! U-343MGa
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 10-09-24; Version: 21
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In book chapter) Human cell culture. Vol. 2. Cancer cell lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York; USA (1999).
//
RX   DOI=10.1007/978-1-4757-1647-4_7;
RA   Ponten J.;
RT   "Neoplastic human glia cells in culture.";
RL   (In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.175-206; Springer; New York; USA (1975).
//
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RA   Nister M., Westermark B.;
RT   "Human glioma cell lines.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York; USA (1994).
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=1847665;
RA   Bongcam-Rudloff E., Nister M., Betsholtz C., Wang J.-L., Stenman G.,
RA   Huebner K., Croce C.M., Westermark B.;
RT   "Human glial fibrillary acidic protein: complementary DNA cloning,
RT   chromosome localization, and messenger RNA expression in human glioma
RT   cell lines of various phenotypes.";
RL   Cancer Res. 51:1553-1560(1991).
//
RX   PubMed=2454731;
RA   Nister M., Libermann T.A., Betsholtz C., Pettersson M.,
RA   Claesson-Welsh L., Heldin C.-H., Schlessinger J., Westermark B.;
RT   "Expression of messenger RNAs for platelet-derived growth factor and
RT   transforming growth factor-alpha and their receptors in human
RT   malignant glioma cell lines.";
RL   Cancer Res. 48:3910-3918(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3675803;
RA   Bigner S.H., Bjerkvig R., Laerum O.D., Muhlbaier L.H., Bigner D.D.;
RT   "DNA content and chromosomes in permanent cultured cell lines derived
RT   from malignant human gliomas.";
RL   Anal. Quant. Cytol. Histol. 9:435-444(1987).
//
RX   PubMed=4134536; DOI=10.1002/ijc.2910120215;
RA   Westermark B.;
RT   "The deficient density-dependent growth control of human malignant
RT   glioma cells and virus-transformed glia-like cells in culture.";
RL   Int. J. Cancer 12:438-451(1973).
//
RX   PubMed=4142792; DOI=10.1111/j.1601-5223.1974.tb01454.x;
RA   Mark J., Ponten J., Westermark B.;
RT   "Cytogentical studies with G-band technique of established cell lines
RT   of human malignant glomas.";
RL   Hereditas 78:304-307(1974).
//
RX   PubMed=4359449; DOI=10.1111/j.1699-0463.1973.tb03573.x;
RA   Westermark B., Ponten J., Hugosson R.;
RT   "Determinants for the establishment of permanent tissue culture lines
RT   from human gliomas.";
RL   Acta Pathol. Microbiol. Scand. A. 81:791-805(1973).
//
RX   PubMed=4369403; DOI=10.1002/1097-0142(197408)34:2<274::AID-CNCR2820340209>3.0.CO;2-4;
RA   Wahlstrom T., Linder E., Saksela E., Westermark B.;
RT   "Tumor-specific membrane antigens in established cell lines from
RT   gliomas.";
RL   Cancer 34:274-279(1974).
//
RX   PubMed=6260907; DOI=10.1097/00005072-198105000-00001;
RA   Bigner D.D., Bigner S.H., Ponten J., Westermark B., Mahaley M.S. Jr.,
RA   Ruoslahti E., Herschman H., Eng L.F., Wikstrand C.J.;
RT   "Heterogeneity of genotypic and phenotypic characteristics of fifteen
RT   permanent cell lines derived from human gliomas.";
RL   J. Neuropathol. Exp. Neurol. 40:201-229(1981).
//
RX   PubMed=10402232; DOI=10.3892/ijo.15.2.237;
RA   Sharif T.R., Sharif M.;
RT   "Overexpression of protein kinase C epsilon in astroglial brain tumor
RT   derived cell lines and primary tumor samples.";
RL   Int. J. Oncol. 15:237-243(1999).
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x; PMCID=PMC8098486;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=11351043; DOI=10.1038/labinvest.3780280;
RA   Hui A.B.-Y., Lo K.-W., Yin X.-L., Poon W.-S., Ng H.-K.;
RT   "Detection of multiple gene amplifications in glioblastoma multiforme
RT   using array-based comparative genomic hybridization.";
RL   Lab. Invest. 81:717-723(2001).
//
RX   PubMed=21061448; DOI=10.1002/jat.1596;
RA   Pereira E.L.R., Lima P.D.L., Khayat A.S., Bahia M.O., Bezerra F.S.,
RA   Andrade-Neto M., Montenegro R.C., Pessoa C., Costa-Lotufo L.V.,
RA   Moraes M.O., Yoshioka F.K.N., Pinto G.R., Burbano R.R.;
RT   "Inhibitory effect of pisosterol on human glioblastoma cell lines with
RT   C-MYC amplification.";
RL   J. Appl. Toxicol. 31:554-560(2011).
//
RX   PubMed=21406405; DOI=10.1158/0008-5472.CAN-10-3112;
RA   Grzmil M., Morin P. Jr., Lino M.M., Merlo A., Frank S., Wang Y.-H.,
RA   Moncayo G., Hemmings B.A.;
RT   "MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta
RT   signaling pathway in human glioblastoma.";
RL   Cancer Res. 71:2392-2402(2011).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072; PMCID=PMC3367844;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26496030; DOI=10.18632/oncotarget.6171; PMCID=PMC4791243;
RA   Patil V., Pal J., Somasundaram K.;
RT   "Elucidating the cancer-specific genetic alteration spectrum of
RT   glioblastoma derived cell lines from whole exome and RNA sequencing.";
RL   Oncotarget 6:43452-43471(2015).
//
RX   PubMed=27582061; DOI=10.1126/scitranslmed.aaf6853;
RA   Allen M., Bjerke M., Edlund H., Nelander S., Westermark B.;
RT   "Origin of the U87MG glioma cell line: good news and bad news.";
RL   Sci. Transl. Med. 8:354re3.1-354re3.4(2016).
//
RX   PubMed=33385022; DOI=10.1016/j.dib.2020.106643; PMCID=PMC7772531;
RA   de Sousa J.F., da Silva P., Serafim R.B., Nociti R.P., Moreira C.G.,
RA   Silva W.A., Valente V.;
RT   "RNA sequencing data of different grade astrocytoma cell lines.";
RL   Data Brief 34:106643.1-106643.13(2021).
//